About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
The University of Kansas Cancer Center
https://www.kucancercenter.org/
2023 Multidisciplinary Oncology Review
2022
Advances in Hematologic Malignancies and Cellular Therapeutics Symposium
2022 Post San Antonio Review
Videos
2021
2021 Virtual KU Hematology and Medical Oncology Review
2021 Post San Antonio Review
2021 KUMC Virtual Multidisciplinary Oncology Review
2020
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases
2020 ASCO Highlights
2019
2019 Post San Antonio Breast Cancer Review
ASH 2019 Review: Current Updates in Hematologic Diseases
2019 Lung Cancer and Head & Neck Cancer Symposium
Hematology & Medical Oncology Review 2019
Lung
Hematologic Malignancies
Gastrointestinal
Head and Neck
Genitourinary
Skin
Palliative
General
Event
2018
ASH: Current Updates in Hematologic Diseases
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
SABCS Data on mTNBC: 1L Chemo + IO in PD-L1+ Disease, Sacituzumab Govitecan, 1L AKTi + Chemo
By
University of Kansas Cancer Center Post San Antonio Review
FEATURING
Sara Tolaney
By
University of Kansas Cancer Center Post San Antonio Review
FEATURING
Sara Tolaney
218 views
February 28, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
2021 Post San Antonio Review
14:55
University of Kansas Cancer Center Post San Antonio Review
50 y/o Premenopausal Woman With T2N1mic BC: Would You Order Gene Exp…
Feat.
P. Sharma,
S. Tolaney,
I. Mayer,
Q. Khan,
J. Balko
14:05
University of Kansas Cancer Center Post San Antonio Review
Challenging Cases of BC: What Should Be the Next Line of Therapy for…
Feat.
P. Sharma,
S. Tolaney,
I. Mayer,
Q. Khan,
J. Balko
12:04
University of Kansas Cancer Center Post San Antonio Review
48 y/o PALB2 Mutation Carrier With T2N0 ER/PR+, HER2- BC: How to Cou…
Feat.
P. Sharma,
J. Klemp,
H. McArthur,
S. Domchek
08:29
University of Kansas Cancer Center Post San Antonio Review
42 y/o With cT2N Grade III TNBC: Does Inclusion of CPIs & Carbop…
Feat.
P. Sharma,
J. Klemp,
H. McArthur,
S. Domchek
07:56
University of Kansas Cancer Center Post San Antonio Review
Expert Discussion on Challenging BC Cases: What Treatment Option to …
Feat.
P. Sharma,
J. Klemp,
H. McArthur,
S. Domchek
19:16
University of Kansas Cancer Center Post San Antonio Review
BC Predisposition Genes San Antonio Review: Who to Test? Should the …
Feat.
S. Domchek
17:29
University of Kansas Cancer Center Post San Antonio Review
SABCS Updates on HR+, HER2- MBC: What Is the Role of HDACi? Does Int…
Feat.
S. Tolaney
07:53
University of Kansas Cancer Center Post San Antonio Review
SABCS Data on mTNBC: 1L Chemo + IO in PD-L1+ Disease, Sacituzumab Go…
Feat.
S. Tolaney
21:41
University of Kansas Cancer Center Post San Antonio Review
Endocrine Resistance in BC: Mechanisms and Treatment Strategies
Feat.
J. Balko
31:02
University of Kansas Cancer Center Post San Antonio Review
Genomic Signatures in Adjuvant Therapy of HR+ EBC: Should We Conside…
Feat.
I. Mayer
